{"title":"按 ICD-O-3 编码划分的日本血液肿瘤类型发病率：全国癌症登记处分析。","authors":"Ayako Muramatsu, Tetsuji Kawakami","doi":"10.1080/20565623.2024.2413801","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> We classified subtypes of hematologic cancer in Japan's National Cancer Registry (NCR) in 2016 by ICD-O-3 code and compared numbers with the Japanese Society of Hematology's Blood Diseases Registry (BDR).<b>Materials & methods:</b> We reviewed data for individual cases, and calculated incidence per 100,000.<b>Results:</b> NCR reported 67,919 cases of hematological cancer, including diffuse large B-cell lymphoma, Not Otherwise Specified (NOS) (11.07 per 100,000), plasma cell myeloma (5.26/100,000), myelodysplastic syndrome, NOS (3.92/100,000), malignant lymphoma, NOS (3.03/100,000), marginal zone B-cell lymphoma, NOS (2.52/100,000) and follicular lymphoma, grade 1 (1.43/100,000). Around 48% of NCR cancers were also reported in the Blood Diseases Registry.<b>Conclusion:</b> ICD-O-3 codes revealed 12,365 additional cases to the 55,554 reported publicly. Accurately updated data are necessary for medical resource planning.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2413801"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495515/pdf/","citationCount":"0","resultStr":"{\"title\":\"Incidence of hematologic cancer types in Japan by ICD-O-3 code: analysis of National Cancer Registry.\",\"authors\":\"Ayako Muramatsu, Tetsuji Kawakami\",\"doi\":\"10.1080/20565623.2024.2413801\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> We classified subtypes of hematologic cancer in Japan's National Cancer Registry (NCR) in 2016 by ICD-O-3 code and compared numbers with the Japanese Society of Hematology's Blood Diseases Registry (BDR).<b>Materials & methods:</b> We reviewed data for individual cases, and calculated incidence per 100,000.<b>Results:</b> NCR reported 67,919 cases of hematological cancer, including diffuse large B-cell lymphoma, Not Otherwise Specified (NOS) (11.07 per 100,000), plasma cell myeloma (5.26/100,000), myelodysplastic syndrome, NOS (3.92/100,000), malignant lymphoma, NOS (3.03/100,000), marginal zone B-cell lymphoma, NOS (2.52/100,000) and follicular lymphoma, grade 1 (1.43/100,000). Around 48% of NCR cancers were also reported in the Blood Diseases Registry.<b>Conclusion:</b> ICD-O-3 codes revealed 12,365 additional cases to the 55,554 reported publicly. Accurately updated data are necessary for medical resource planning.</p>\",\"PeriodicalId\":12568,\"journal\":{\"name\":\"Future Science OA\",\"volume\":\"10 1\",\"pages\":\"2413801\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495515/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Science OA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/20565623.2024.2413801\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2024.2413801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Incidence of hematologic cancer types in Japan by ICD-O-3 code: analysis of National Cancer Registry.
Aim: We classified subtypes of hematologic cancer in Japan's National Cancer Registry (NCR) in 2016 by ICD-O-3 code and compared numbers with the Japanese Society of Hematology's Blood Diseases Registry (BDR).Materials & methods: We reviewed data for individual cases, and calculated incidence per 100,000.Results: NCR reported 67,919 cases of hematological cancer, including diffuse large B-cell lymphoma, Not Otherwise Specified (NOS) (11.07 per 100,000), plasma cell myeloma (5.26/100,000), myelodysplastic syndrome, NOS (3.92/100,000), malignant lymphoma, NOS (3.03/100,000), marginal zone B-cell lymphoma, NOS (2.52/100,000) and follicular lymphoma, grade 1 (1.43/100,000). Around 48% of NCR cancers were also reported in the Blood Diseases Registry.Conclusion: ICD-O-3 codes revealed 12,365 additional cases to the 55,554 reported publicly. Accurately updated data are necessary for medical resource planning.
期刊介绍：
Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
